Hjem
Sites

Områder

Vælg et område

Check de forskellige Progress in Mind indholdsområder.

Vælg land

Statusmeddelelse

You can use hashed link to view this node.
Skizofreni

Supersensitivitet (18 min.)

Her diskuteres og forklares begrebet supersensitivering i sammenhæng med antipsykotisk behandling med dopaminreceptorantagonister. Hvorfor opstår det? Og er der nogen forskel mellem antagonister og partielle agonister?

Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
Not located in Brazil?
Go to a different regional HUB
Continue to Progress in MindContinue to Progress in Mind BrazilContinue to Progress in Mind MENAContinue to Progress in Mind SpainContinue to Progress in Mind ItalyContinue to Progress in Mind GreeceContinue to Progress in Mind South East AsiaContinue to Progress in Mind Middle East & AfricaContinue to Progress in Mind United KingdomContinue to Progress in Mind SwedenContinue to Progress in Mind NorgeContinue to Progress in Mind DenmarkContinue to Progress in Mind Japan RCContinue to Progress in Mind БългарияContinue to Progress in Mind IsraelContinue to Progress in Mind SwedenContinue to Progress in Mind FinlandContinue to Progress in Mind UkraineContinue to Progress in Mind Belgium & LuxembourgContinue to Progress in Mind SwitzerlandContinue to Progress in Mind GermanyContinue to Progress in Mind Austria
Du forlader nu Progress in Mind
Fortsæt til
Annullér
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
Informationerne på denne side er udelukkende forbeholdt sundhedspersoner
Accepter
Nej tak
Congress
Register for access to Progress in Mind in your country
Annullér
New member registration